Sponsored content brought to you by

Catalent logo

This year marks the 40th anniversary of Genetic Engineering & Biotechnology News (GEN), which has been providing the global biotechnology industry with critical news, practical information, and in-depth analysis since the publication’s inception. To help celebrate its anniversary, GEN is running a special section in each issue that takes a look back and, more importantly, discusses what might be in store in the future regarding  a number of key biotech fields, including monoclonal antibodies (mAbs), proteomics, the human genome, gene therapy, bioprocessing, precision medicine, agricultural biotechnology, vaccines, next-generation sequencing, and epigenetics.

This issue of GEN 40 highlights the announcement in 2000 by the International Human Genome Sequencing Consortium that a “working draft” of the human genome had been completed and made available for further study.

“Today, we are learning the language in which God created life,” said President Bill Clinton at the time, paraphrasing Galileo. “[We] have caught the first glimpse of our own instruction book. It will revolutionize the diagnosis, prevention, and treatment of most, if not all, human diseases.”

Today, insights gained from research on the human genome have impacted virtually every aspect of biology and medicine.

It is with great pleasure that Catalent Biologics supports the GEN 40 program and takes this opportunity to look at how the industry has changed over the last 40 years.

Catalent Biologics, a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates (ADCs), congratulates GEN on its anniversary. With over 20 years of proven expertise and advanced technologies, Catalent Biologics has played a major role in helping to foster rapid breakthroughs in R&D and manufacturing from traditional mAbs to next-generation therapies. Catalent Biologics will help you deliver better biologic therapies to patients quickly and reliably.

Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. Catalent’s GPEx® cell line development platform is a proven technology that generates high-performance, highly stable, production cell lines, and its SMARTag® bioconjugation platform provides site-specific conjugation using naturally occurring modifications to generate better-tolerated ADCs with potential for a wider clinical therapeutic index.

Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors, lentiviral vectors, and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. When Catalent acquired MaSTherCell, it added expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has worked with industry-leading partners across 70+ clinical and commercial programs.

 

For more information, visit biologics.catalent.com